Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from CanSino Biologics, Inc. Class H ( (HK:6185) ).
CanSino Biologics Inc. has established an Audit Committee to enhance its governance structure and ensure effective oversight and management by the board of directors. This move is aimed at improving the company’s internal control systems, facilitating communication with external audit firms, and assessing risks related to significant investments. The committee will consist of non-executive directors, with a majority being independent, to ensure unbiased supervision and verification of audits.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily engaged in the development and production of vaccines. The company focuses on providing innovative vaccine solutions to address global health challenges.
Average Trading Volume: 2,081,073
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.13B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.